



CASE CT-2746 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Samuel J. DuBoff  
Type or print name

*Samuel J. DuBoff*  
Signature

October 24, 2003  
Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF

REGUEIRO-REN ET AL.

APPLICATION NO: 10/622,687

FILED: JULY 18, 2003

FOR: INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC UREIDO  
AND THIOUREIDO PIPERAZINE DERIVATIVES

MAIL STOP: DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(203) 677-7787

  
\_\_\_\_\_  
Samuel J. DuBoff  
Attorney for Applicants  
Reg. No. 25,969

Date: 10/24/03

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
CT-2746 NP  
APPLICATION NO.  
10/622,687  
APPLICANT  
Regueiro-Ren et al.  
FILING DATE  
July 18, 2003

Group --

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,124,327	6/23/92	W. J. Greenlee, et al			
	AB	5,424,329	6/13/95	D. H. Boschelli, et al			
	AC	5,023,265	6/11/91	M. H. Scherlock, et al			
	AD	6,469,006	10/22/02	W. S. Blair, et al			
	AE	6,476,034	11/5/02	T. Wang, et al			
	AF	6,573,262	6/3/03	O. B. Wallace, et al			
	AG						
	AH						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AI	EP 0530907A1	3/10/93	European Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AJ	WO 93/01181	1/21/93	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AK	WO 95/04742	2/16/95	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AL	WO 96/11929	4/25/96	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AM	WO 02/062423	8/15/02	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 99/51224	10/14/99	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 03/041644	5/22/03	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>
	AR						<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

	AS	M. Font, et al, "Indoles and Pyridazino[4,5- <i>b</i> ]Indoles as Nonnucleoside Analog Inhibitors of HIV-1 Reverse Transcriptase," EUR. J. MED. CHEM., <b>30</b> , pp. 963-971, 1995
	AT	D. L. Romero, et al, J. MED. CHEM., <b>36</b> , pp. 1505-1508, 1993
	AU	S. D. Young, et al, "2-Heterocyclic Indole-3-Sulfones as Inhibitors of HIV-1 Reverse Transcriptase," BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, <b>5</b> (5), pp. 491-496, 1995

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
CT-2746 NP  
APPLICATION NO.  
10/622,687  
APPLICANT  
Regueiro-Ren et al.  
FILING DATE  
July 18, 2003

Group --

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AV	M. J. Genin, et al, "Synthesis and Bioactivity of Novel Bis(Heteroaryl)Piperazine (BHAP) Reverse Transcriptase Inhibitors: Structure-Activity Relationships and Increased Metabolic Stability of Novel Substituted Pyridine Analogs," J. MED. CHEM., <b>39</b> , pp. 5267-5275, 1996
AW	R. Silvestri, et al, ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, <b>9</b> , pp. 139-148, 1998
AX	A. Fredenhagen, et al, "Semicochlindinol A and B: Inhibitors of HIV-1 Protease and EGF-R Protein Tyrosine Kinase Related to Asterriquinones Produced by the Fungus <i>Chrysosporium Merdarium</i> ," JOURNAL OF ANTIBIOTICS, <b>50</b> (5), pp. 395-401, 1997
AY	M. Kato, et al, "New 5-HT <sub>3</sub> (Serotonin-3) Receptor Antagonists. IV. Synthesis and Structure-Activity Relationships of Azabicycloalkaneacetamide Derivatives," CHEM. PHARM. BULL., <b>43</b> (8), pp. 1351-1357, 1995
AZ	V. Levacher, et al, "Broadening in the Scope of NADH Models by Using Chiral and Non-Chiral Pyrrolo [2,3-b]Pyridine Derivatives," TETRAHEDRON, <b>47</b> (3), pp. 429-440, 1991
BA	
BB	
BC	
BD	
BE	
BF	
BG	
BH	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.